Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Detalles Bibliográficos
Autores principales: Nuijten, M, Mickisch, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844043/
http://dx.doi.org/10.1038/sj.bjc.6605613
_version_ 1782179277563756544
author Nuijten, M
Mickisch, G
author_facet Nuijten, M
Mickisch, G
author_sort Nuijten, M
collection PubMed
description
format Text
id pubmed-2844043
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28440432010-07-29 Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival Nuijten, M Mickisch, G Br J Cancer Corrigendum Nature Publishing Group 2010-03-16 2010-03-16 /pmc/articles/PMC2844043/ http://dx.doi.org/10.1038/sj.bjc.6605613 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Corrigendum
Nuijten, M
Mickisch, G
Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title_full Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title_fullStr Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title_full_unstemmed Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title_short Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title_sort letter to the editor: sun vs bevþifn in first-line mrcc therapy: no evidence for a statistically significant difference in progression-free survival
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844043/
http://dx.doi.org/10.1038/sj.bjc.6605613
work_keys_str_mv AT nuijtenm lettertotheeditorsunvsbevþifninfirstlinemrcctherapynoevidenceforastatisticallysignificantdifferenceinprogressionfreesurvival
AT mickischg lettertotheeditorsunvsbevþifninfirstlinemrcctherapynoevidenceforastatisticallysignificantdifferenceinprogressionfreesurvival

Ejemplares similares